Previous 10 | Next 10 |
Pixabay Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical ...
Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the following upcoming investor c...
Preface Shares of Neurocrine Biosciences ( NBIX ) are up nearly 40% since I published the article , in December 2018, citing my belief that shares of NBIX would see $100 again. At that time, Neurocrine had revealed disappointing data in Tourette's and traded in the low $70s. Since then...
Voyager Therapeutics, Inc. (VYGR) Q2 2019 Earnings Conference Call August 09, 2019 08:00 AM ET Company Participants Allison Dorval - Chief Financial Officer Andre Turenne - President and Chief Executive Officer Omar Khwaja - Chief Medical Officer and Head of Research and Developm...
The following slide deck was published by Voyager Therapeutics, Inc. in conjunction with this Read more ...
Voyager Therapeutics (NASDAQ: VYGR ): Q2 EPS of $0.29 may not be comparable to consensus of -$0.81. More news on: Voyager Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Gained worldwide rights to VY-HTT01 for Huntington’s disease, expanding wholly-owned pipeline Presented additional Phase 1b results for VY-AADC in patients with Parkinson’s disease at the 2019 American Academy of Neurology (AAN) Annual Meeting Strengthened leadership...
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its second quarter 2019 financial results...
Neurocrine Biosciences ( NBIX ) was never set up for a great year in 2019 from a clinical data/pipeline perspective, but management is compensating so far with strong sales execution with its approved drug Ingrezza. With the company now free cash flow positive, management has a lot of option...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...